Company intelligence / Profile preview

Ocular Systems

Winston-Salem, North Carolina, United States

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

OSI was the first U.S. company to provide surgeons with prepared corneal tissue for transplant and developed the EndoSerter® device for delivering corneal allografts during DSEK procedures. The company supplied over 20,000 transplants in the U.S. before being acquired by SightLife[1][3].

Therapeutic areas: Ophthalmology
Modalities: DeviceBiologic (human corneal tissue for transplant)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

Omnifocal Intra Ocular Lens

Commercial

Indications: Cataract, Presbyopia

Partnerships

Accredited eye banks across the United States[3]

Beyond the preview

Go deeper on Ocular Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocular Systems.

Explore the full profile